These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2005-004939-22 A PHASE I/II EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH RECURRENT OR METASTATIC NON-NASOPHARYNGEAL HEAD AND NECK CANCER not-yet-due
Exempt 2006-007082-36 A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethasone in patients with primary (AL) systemic amyloidosis 2011-11-30 not-yet-due
Not reported Terminated 2007-001555-19 DOCETAXEL COMBINED WITH PULSATILE ERLOTINIB (TARCEVA) IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) 2010-05-31 due-trials
Exempt 2007-006656-19 INVESTIGATION OF THE EFFICACY OF LAPATINIB MONOTHERAPY AND TEMOZOLOMIDE PLUS LAPATINIB COMBINATION, IN RECURRENT HIGH GRADE GLIOMAS. A PHASE I/II STUDY. 2014-10-02 not-yet-due
Exempt 2008-002791-10 GEMCITABINE COMBINED WITH THE mTOR INHIBITOR TEMSIROLIMUS (CCI-779) IN PATIENTS WITH INOPERABLE OR METASTATIC PANCREATIC CANCER 2015-05-27 not-yet-due
Completed, but no date Terminated 2008-007925-38 STUDY OF THE mTOR INHIBITOR TEMSIROLIMUS (CCI-779) IN PATIENTS WITH CA125 ONLY RELAPSE OF OVARIAN CANCER A phase II study by the Hellenic Cooperative Oncology Group bad-data
Reported results 2009-012655-26 A SINGLE-ARM, MULTICENTER, PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH CAPECITABINE / OXALIPLATIN IN FIRST-LINE, WILD-TYPE K-RAS METASTATIC COLORECTAL CANCER PATIENTS 2014-08-26 due-trials
Reported results 2009-013128-22 Lapatinib and Whole Brain Radiotherapy for patients with brain metastases from lung and breast tumors. A phase II study of the Hellenic Cooperative Oncology Group (HeCOG). 2014-08-04 due-trials
Not reported Terminated 2010-020664-38 Efficacy and safety of Bevacizumab/Temsirolimus combination after first-line Bevacizumab/IFN combination in advanced renal cell carcinoma 2015-07-24 due-trials
Not reported 2011-003625-97 Phase II study of cabazitaxel as 2nd-line treatment in patients with HER-2 negative metastatic breast cancer previously treated with taxanes 2017-07-20 due-trials
Ongoing 2011-006160-48 Phase II multicenter single-arm study evaluating the safety and efficacy of everolimus as a first-line treatment in newly-diagnosed patients with advanced GI neuroendocrine tumors. not-yet-due
Ongoing 2011-006198-25 A Phase II, single-arm clinical trial of administration of cisplatin and 5-fluorouracil with afatinib as first-line therapy in patients with inoperable gastric or gastroesophageal junction cancer not-yet-due
Completed, report not yet due Terminated 2012-001705-24 Phase II single-arm study of first line treatment with gemcitabine and pazopanib in patients with inoperable locally advanced or metastatic biliary tree cancer (cholangiocarcinoma or gallbladder carci... 2018-09-28 not-yet-due
Not reported 2013-002567-26 Single-arm phase II study of maintenance therapy with aflibercept after first-line treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients 2017-09-25 due-trials
Ongoing 2014-004485-21 A study of cabazitaxel treatment in castration resistant bone metastatic prostate cancer patients evaluating the tumor microenvironment not-yet-due
Ongoing 2015-005268-41 Phase ΙΙ (window) preoperative study of olaparib with or without cisplatin or no treatment in patients with histologically proven squamous cell carcinoma of the head and neck who are candidates for su... not-yet-due
Ongoing 2016-003644-37 Single-arm phase II study of panitumumab rechallenge in combination with oxaliplatin or irinotecan-based chemotherapy in patients with RAS wild type advanced colorectal cancer. not-yet-due
Ongoing 2017-004784-12 Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer (SCLC) not-yet-due
Exempt 2017-004792-30 Phase Ib-II study of Ramucirumab combined with standard Nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma not-yet-due